In parallel with mazisotine’s shelving, Lilly added a phase 1 NaV1.8 inhibitor from its SiteOne Therapeutics acquisition to ...
Currently incurable, peripheral neuropathies are common neurological complications of chemotherapy, causing persistent pain, ...
Topline data were announced from a phase 3 trial evaluating secukinumab in patients with polymyalgia rheumatica.
Among adults with type 2 diabetes, SGLT-2 inhibitors were linked to lower risk for autoimmune rheumatic diseases compared with sulfonylureas.
Rocatinlimab shows real-world promise for moderate to severe AD, enhancing treatment efficacy and reducing steroid reliance, explains Emma Guttman-Yassky, MD, PhD.
News Medical on MSN
New chemotherapeutic agent shows remarkable efficacy against multiple tumor types
A research team led by the Medical University of Vienna, the HUN-REN Research Centre for Natural Sciences and the Eötvös Loránd University in Budapest has developed a groundbreaking new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback